Written and maintained by CASRAI Editorial Board
Published
On this page
Title 21 CFR § 820.70 is the United States Food and Drug Administration (FDA) regulation governing production and process controls for medical device manufacturers. Codified under Subpart G of the Quality System Regulation and preserved through the Quality Management System Regulation (QMSR) transition, § 820.70 mandates that device manufacturers establish, maintain, and monitor controlled production environments, validated automated software, equipment maintenance schedules, contamination safeguards, and documented manufacturing procedures to guarantee that finished medical devices consistently conform to their approved release specifications.
This page describes products and general use; it is not medical advice.
What It Is and Who Runs It
Production and process controls under 21 CFR § 820.70 form the operational core of medical device manufacturing quality systems in the United States. Administered and enforced by the FDA Center for Devices and Radiological Health (CDRH), § 820.70 derives its statutory authority from Section 520(f) of the Federal Food, Drug, and Cosmetic Act (FD and C Act), codified at 21 U.S.C. § 360j(f). Under Section 501(h) of the FD and C Act (21 U.S.C. § 351(h)), any medical device manufactured in an establishment that fails to comply with applicable requirements of 21 CFR Part 820 is legally classified as adulterated, subjecting the manufacturer to regulatory injunctions, seizures, warning letters, or import alerts.
On February 2, 2024, the FDA published its final rule titled “Medical Devices; Quality System Regulation Amendments” (89 FR 7496), establishing the Quality Management System Regulation (QMSR) effective February 2, 2026. The QMSR incorporates by reference ISO 13485:2016 and the definitions of ISO 9000:2015 Clause 3. While the QMSR designated legacy Subparts C through O as reserved, the substantive requirements of 21 CFR § 820.70 remain fully enforced through ISO 13485:2016 Clause 7.5 (Production and service provision) and Clause 4.1.6 (Software validation).
Eligibility and Scope Under FDA Regulations
The obligations set forth in 21 CFR § 820.70 apply universally to all domestic and foreign establishments that design, manufacture, assemble, package, sterilize, or process finished medical devices distributed in the United States. Unlike design controls under 21 CFR § 820.30 (which exempt certain Class I devices unless automated with software or specifically listed), production and process controls apply across device classifications:
- Class I Devices: Subject to general production controls, including documented assembly instructions, contamination management, and basic equipment maintenance, unless an explicit exemption is listed under 21 CFR Parts 862 through 892.
- Class II Devices: Subject to complete § 820.70 controls, including formal environmental monitoring, calibrated equipment tracking, documented change controls, and software validation for automated test fixtures.
- Class III Devices: Subject to comprehensive process capability analysis, validated cleanroom bioburden controls, automated execution system validation, and statistical process controls with heightened regulatory scrutiny.
- Specification Developers and Contract Manufacturers: Even when a brand owner outsources physical assembly to a contract manufacturer, the legal manufacturer remains responsible for verifying that the facility maintains compliant process controls pursuant to quality agreements.
What 21 CFR 820.70 Requires for Production and Process Controls
Section 820.70 establishes nine interrelated operational subsections that govern how manufacturing facilities design, execute, monitor, and adapt physical and computerized processes:
General Process Controls (§ 820.70(a))
Manufacturers must develop, conduct, control, and monitor production processes to ensure that finished devices conform strictly to specifications. Where deviations from device specifications could occur as a consequence of the manufacturing process, written process control procedures must include documented instructions and SOPs defining production methods, continuous or lot-by-lot monitoring of critical process parameters and component characteristics, compliance with reference standards, pre-operational approval of processes and equipment, and objective workmanship criteria expressed through documented visual standards or approved golden samples.
Production and Process Changes (§ 820.70(b))
Subsection 820.70(b) requires manufacturers to maintain documented procedures for initiating, reviewing, approving, and executing changes to any specification, method, process, or procedure. Before any process change is introduced into commercial production, the manufacturer must conduct verification or, where appropriate, process validation in accordance with § 820.75. All changes must be formally approved in accordance with document control requirements under § 820.40.
Environmental Control (§ 820.70(c))
Where environmental conditions could reasonably be expected to have an adverse impact on device quality, manufacturers must establish and maintain procedures to control and monitor the physical environment. This encompasses cleanroom temperature, relative humidity, airborne viable and non-viable particulate counts, and differential air pressures. Environmental monitoring systems and air filtration equipment must be periodically inspected and tested to verify sustained operational integrity, with all findings documented and reviewed.
Personnel Hygiene and Cleanliness (§ 820.70(d))
Manufacturers must establish and enforce requirements for personnel health, cleanliness, personal hygiene practices, and protective gowning. Employees who exhibit medical conditions that could adversely affect product quality must be excluded from direct contact with product or cleanroom environments. Maintenance personnel and outside contractors temporarily entering controlled environments must be trained in gowning and contamination protocols or supervised by qualified personnel.
Contamination Control (§ 820.70(e))
Procedures must be maintained to prevent equipment, raw materials, in-process subassemblies, and finished devices from coming into contact with particulate, chemical, or biological contaminants. Measures include prohibiting particulate-shedding cardboard packaging inside cleanroom suites, enforcing line clearance between lots, and dedicated cleaning regimens for tooling.
Buildings and Facility Design (§ 820.70(f))
Physical plant facilities must be of suitable design, construction, and layout to provide adequate space for orderly manufacturing operations, maintenance access, material flow, and cleaning. The physical layout must enforce unidirectional material transfer and spatial segregation between incoming receiving, storage, assembly, quarantine, packaging, and finished goods warehousing to prevent mix-ups.
Equipment Maintenance, Inspection, and Adjustment (§ 820.70(g))
Manufacturing equipment must meet engineering specifications and be designed and placed to facilitate maintenance, adjustment, and cleaning. Subsection 820.70(g) enforces three specific safeguards:
- Maintenance Schedules (§ 820.70(g)(1)): Written preventive maintenance schedules defining cleaning, lubricating, and overhaul intervals, with completed actions documenting the date and individual technician.
- Periodic Inspection (§ 820.70(g)(2)): Independent inspections at established intervals to ensure technicians adhere to maintenance schedules, with all inspection findings documented.
- Adjustment Limits and Tolerances (§ 820.70(g)(3)): Allowable calibration tolerances and operational limitations visibly posted on or near equipment requiring periodic adjustment, or accessible via digital operator interfaces.
Manufacturing Material Management (§ 820.70(h))
Manufacturing materials—substances used during processing that are not intended to remain in the finished device, such as machine lubricants, mold release agents, degreasing solvents, and cleaning detergents—must be controlled. Where these materials could adversely affect device quality, manufacturers must establish procedures for their use and documented removal or reduction to validated safe thresholds.
Automated Processes and Software Validation (§ 820.70(i))
Whenever computers, programmable logic controllers (PLCs), or automated data processing systems are used as part of production operations or the broader quality system, the manufacturer must validate the computer software for its intended use according to an established protocol. All software revisions, configuration updates, and macro patches must be validated prior to commercial issuance, with all validation test protocols, objective execution results, and approvals archived.
Application and Compliance Steps for Manufacturers
Establishing compliance with 21 CFR § 820.70 requires a systematic engineering and quality management approach. Medical device organizations implement process controls through six sequential steps:
- Process Characterization and Specification Mapping: Review device master records to identify critical quality attributes (CQAs) and critical process parameters (CPPs), establishing which process steps require active monitoring and boundary tolerances under § 820.70(a).
- Standard Operating Procedure and Workmanship Standard Authoring: Author and approve detailed SOPs, routing cards, and visual defect standards. Golden samples representing marginal acceptability and defect states are indexed, tagged, and displayed at assembly benches.
- Environmental and Facility Qualification: Cleanroom environments, laminar flow hoods, HVAC air handling units, and compressed air systems undergo installation and operational qualification under § 820.70(c).
- Equipment Maintenance and Calibration Setup: All production machinery, torque drivers, and assembly fixtures are tagged with equipment IDs, added to preventive maintenance schedules, and assigned calibrated operating ranges under § 820.70(g).
- Computerized System and Automation Validation: In alignment with the FDA CSA guidance and the FDA General Principles of Software Validation, all automated manufacturing software and test fixtures undergo risk-based protocol validation under § 820.70(i).
- Change Control Integration and Routine Auditing: The facility establishes formal engineering change order (ECO) workflows tied directly to § 820.70(b), accompanied by routine in-process auditing and statistical sampling plans.
Typical Timeline Phases and Inspection Milestones
Implementing or upgrading a production facility to satisfy 21 CFR § 820.70 and harmonized QMSR standards is an extensive undertaking. Device manufacturers structure implementation across six sequential timeline phases:
- Phase 1: Process Mapping and Risk Analysis: Engineering teams document process flow diagrams, conduct process failure mode and effects analysis (pFMEA), and establish formal control plans linking device specifications to shop-floor monitoring steps.
- Phase 2: Facility Zoning and Environmental Setup: Cleanroom construction, differential pressure balancing, HEPA filter integrity testing, and initial viable particulate baseline mapping are completed.
- Phase 3: Equipment Qualification and Calibration Scheduling: Installation and operational qualification protocols for all production machinery are executed, and maintenance placards and tolerance tags are affixed to physical assets.
- Phase 4: Automated Software and Tooling Validation: Automated production software, digital travelers, inspection algorithms, and quality databases undergo protocol execution and testing in accordance with § 820.70(i).
- Phase 5: Process Verification and Operator Qualification: Pilot manufacturing runs test the robustness of SOPs, personnel gowning routines, and manufacturing material removal protocols. Operators are qualified on workmanship standards.
- Phase 6: Inspection Readiness and Internal Auditing: Internal quality audit teams execute mock inspections, verifying that maintenance records, environmental charts, change logs, and validation binders are complete and retrievable.
Common Compliance Mistakes and 483 Observations
FDA establishment inspections routinely uncover serious systemic gaps in production and process control systems. Review of FDA Form 483 inspectional observations and CDRH Warning Letters reveals recurring compliance pitfalls:
- Uncontrolled Process Modifications (§ 820.70(b)): Line operators or engineers adjust thermal bonding temperatures, cycle speeds, or cutting dimensions on the shop floor without initiating an engineering change order, re-validating the altered parameters, or updating the device master record.
- Inadequate Cleanroom and Environmental Monitoring (§ 820.70(c)): Environmental control procedures mandate periodic settling plate sampling, but logs show missed sampling intervals, uninvestigated excursions exceeding action limits, or cleanrooms operating with negative differential pressure relative to ambient hallways.
- Gowning and Contamination Protocol Non-Compliance (§ 820.70(d) and (e)): Operators wearing improper cleanroom attire, exposed facial hair, or storing particulate-shedding cardboard boxes inside cleanroom suites, creating direct product contamination hazards.
- Missing or Incomplete Equipment Maintenance Documentation (§ 820.70(g)): Maintenance schedules require monthly lubrication and bearing replacement, but logbooks reveal multi-month gaps with no documented justification, or maintenance records signed off weeks after the scheduled due date.
- Unposted Tolerances and Arbitrary Equipment Adjustments (§ 820.70(g)(3)): Technicians adjust belt tension, pneumatic pressure regulators, or ultrasonic welding horns based on informal habit rather than posting and adhering to documented engineering tolerances.
- Failure to Validate Automated Software and Spreadsheets (§ 820.70(i)): Manufacturing lines utilize custom spreadsheets with embedded formulas for device release calculations or automated PLC controllers without pre-approved validation protocols, challenge testing, or version controls.
- Unverified Manufacturing Material Removal (§ 820.70(h)): Facilities use cleaning solvents, mold release agents, or lubricants during assembly without documented chemical residue studies proving the agent has been completely removed or reduced below toxicological limits.
Related Regulations and International Standards
Understanding 21 CFR § 820.70 requires viewing it within the broader landscape of national regulations, international quality management standards, and companion GxP rules. Device makers should consult our comprehensive 21 CFR Part 820 guide and review core current good manufacturing practice regulations to understand broader compliance obligations.
The table below summarizes how 21 CFR § 820.70 compares with related regulatory standards and international quality frameworks:
| Regulatory Standard or Code | Primary Focus and Authority | Key Overlap with 21 CFR 820.70 | Core Operational Differences |
|---|---|---|---|
| FDA 21 CFR § 820.75 (Process Validation) | FDA statutory requirement under 21 CFR Part 820 | Directly cross-referenced in § 820.70(b) for process and specification changes | § 820.70 governs routine process controls and monitoring; § 820.75 applies when results cannot be fully verified by subsequent inspection |
| ISO 13485:2016 Clause 7.5 (Production and Service) | International consensus standard IBR’d under FDA QMSR | Direct harmonized counterpart for manufacturing controls, cleanliness, and servicing | ISO 13485 structures requirements under Clause 7.5.1 (General), 7.5.2 (Cleanliness), and 7.5.6 (Process Validation); enforced via FD and C Act Section 501(h) |
| ISO 13485:2016 Clause 4.1.6 and Clause 7.5.6 | International standard for QMS software validation | Corresponds directly to § 820.70(i) automated software validation | Detailed validation checklists can be reviewed in our ISO 13485 software validation checklist guide |
| FDA 21 CFR Part 11 (Electronic Records and Signatures) | FDA regulation for digital systems and audit trails | Applies to computerized automated systems validated under § 820.70(i) | Part 11 governs electronic signature validity, data integrity, and system audit trails; § 820.70(i) requires validating that software performs its intended production function |
| ISO 14644-1 / ISO 14644-2 (Cleanroom Standards) | International cleanroom airborne particulate classifications | Provides technical methodology for environmental control under § 820.70(c) | ISO 14644 defines airborne particle limits; § 820.70(c) mandates the regulatory requirement to control and inspect the system |
| cGMP Facility Principles (21 CFR Part 211 / Part 820) | Good manufacturing practice regulatory framework | Aligns building design, contamination segregation, and HVAC maintenance | Physical facility requirements and airflow segregation are further examined in our cGMP facility requirements reference |
The data table below provides a comprehensive comparison of all nine subsections of 21 CFR 820.70, detailing the core regulatory requirement, mandatory documentation artifacts, primary inspection focus areas, and corresponding harmonized clauses under ISO 13485:2016 and the FDA QMSR framework.
Frequently asked questions
What are the key requirements of 21 CFR 820.70?
The key requirements of 21 CFR § 820.70 encompass nine operational areas: general process controls and SOPs (§ 820.70(a)), change control and re-validation (§ 820.70(b)), cleanroom and environmental monitoring (§ 820.70(c)), personnel hygiene and gowning (§ 820.70(d)), contamination control (§ 820.70(e)), building design and mix-up prevention (§ 820.70(f)), equipment maintenance schedules, inspections, and adjustment tolerances (§ 820.70(g)), manufacturing material removal (§ 820.70(h)), and automated software validation (§ 820.70(i)).
When are documented process control procedures explicitly required?
Documented process control procedures are required under § 820.70(a) wherever deviations from device specifications could occur as a result of the manufacturing process. If the absence of a written procedure or monitoring instruction could lead to non-conforming finished product, manufacturers must establish and maintain written instructions, parameter monitoring plans, reference standards, and workmanship acceptance criteria.
How does 21 CFR 820.70 relate to Process Validation under 21 CFR 820.75?
Section 820.70 governs day-to-day routine manufacturing controls, equipment maintenance, and parameter monitoring. In contrast, 21 CFR § 820.75 governs process validation, which is mandatory whenever process output cannot be fully verified by subsequent inspection and testing. In addition, § 820.70(b) explicitly links to § 820.75 by requiring that changes to production processes, methods, or specifications be verified or validated according to § 820.75 before implementation.
How should environmental and cleanroom controls under 820.70(c) be handled?
Environmental controls under § 820.70(c) require written procedures to control and monitor conditions that could affect device quality, including temperature, humidity, air pressure differentials, and airborne particulate levels. Manufacturers must periodically inspect environmental systems and air filters to verify proper operation, maintaining dated records of all inspections, calibrations, and maintenance.
What are common compliance pitfalls under 21 CFR 820.70(i) for automated software?
Frequent pitfalls under § 820.70(i) include failing to validate custom or off-the-shelf software used in production or quality systems, using unvalidated spreadsheets with formulas for product release calculations, and deploying software updates, macros, or scripts without re-validation under an established protocol. Manufacturers must maintain pre-approved test protocols, documented test results, and formal approvals.
How does the transition to the Quality Management System Regulation (QMSR) affect 21 CFR 820.70?
Under the FDA QMSR final rule (89 FR 7496, effective February 2, 2026), 21 CFR Part 820 incorporates ISO 13485:2016 by reference, designating legacy Subpart G as reserved. Substantive requirements of § 820.70 remain fully enforced through ISO 13485 Clause 7.5 (Production and service provision), Clause 7.5.1 (Control of production), Clause 7.5.2 (Cleanliness), Clause 7.5.6 (Process validation), and Clause 4.1.6 (Software validation).
Sources
- Legal Information Institute, Cornell Law School: 21 CFR § 820.70 – Production and process controls, checked 2026-11-20
- U.S. Government Publishing Office: 21 CFR 820.70 – Production and process controls (eCFR XML), checked 2026-11-20
- Federal Register: Medical Devices; Quality System Regulation Amendments (QMSR Final Rule, 89 FR 7496), checked 2026-11-20
- U.S. Food and Drug Administration: Quality Management System Regulation (QMSR) Overview, checked 2026-11-20
- U.S. Food and Drug Administration: General Principles of Software Validation; Final Guidance for Industry and FDA Staff, checked 2026-11-20
- eCFR: 21 CFR Part 820 — Quality Management System Regulation, checked 2026-11-20
Data: 21 CFR 820.70 Subsections, Compliance Requirements, and QMSR ISO 13485 Alignment Matrix
Comparison matrix detailing the nine subsections of FDA 21 CFR 820.70 production and process controls, required regulatory documentation, critical inspection focus areas, and corresponding clauses under the Quality Management System Regulation (QMSR) incorporating ISO 13485:2016. Compiled from Title 21 of the Code of Federal Regulations, the QMSR Final Rule (89 FR 7496), and FDA software validation guidance.
Period covered: 2024/2026. Coverage: United States.
| CFR Subsection | Core Requirement | Mandatory Records | Inspection Focus Area | QMSR / ISO 13485 Alignment |
|---|---|---|---|---|
| 820.70(a) General Process Controls | Develop, conduct, control, and monitor production processes to ensure device conforms to specifications | Documented SOPs, work instructions, routing sheets, approved golden samples, parameter logs | Shop floor adherence to procedures, parameter monitoring logs, workmanship defect catalogs | ISO 13485:2016 Clause 7.5.1 (Control of production and service provision) |
| 820.70(b) Production and Process Changes | Establish procedures for changes to specifications, methods, processes, or procedures with verification/validation | Engineering change orders (ECOs), change review records, validation reports per § 820.75, sign-offs | Unauthorized parameter tweaks, lack of re-validation before commercial release | ISO 13485:2016 Clause 7.3.9 (Control of design and development changes) and Clause 7.5.6 |
| 820.70(c) Environmental Control | Control and monitor environmental conditions that could adversely affect product quality | Cleanroom monitoring procedures, viable/non-viable particulate logs, differential pressure charts, HVAC service logs | Uninvestigated cleanroom excursions, negative pressure issues, overdue HEPA certifications | ISO 13485:2016 Clause 6.4.1 (Work environment) and Clause 7.5.2 (Cleanliness of product) |
| 820.70(d) Personnel Cleanliness & Health | Establish requirements for health, hygiene, clothing, and gowning to prevent contamination | Gowning SOPs, hygiene training records, contractor escort logs, medical exclusion records | Operator gowning violations, exposed facial hair, untrained temporary technicians in cleanrooms | ISO 13485:2016 Clause 6.4.1 (Work environment - personnel requirements) |
| 820.70(e) Contamination Control | Establish procedures to prevent equipment or product contamination by foreign substances | Line clearance logs, cleanroom material transfer SOPs, tool cleaning records, waste handling procedures | Cardboard shipping containers in cleanrooms, chemical residue accumulation, mix-up prevention | ISO 13485:2016 Clause 7.5.2 (Cleanliness of product) and Clause 6.4.2 (Contamination control) |
| 820.70(f) Buildings and Facility Design | Maintain suitable building design, layout, and space to perform operations and prevent mix-ups | Facility layout diagrams, material flow maps, spatial segregation SOPs, quarantine area controls | Congestion in assembly areas, lack of physical segregation between quarantine and released stock | ISO 13485:2016 Clause 6.3 (Infrastructure) and Clause 6.4 (Work environment) |
| 820.70(g) Equipment Maintenance & Adjustment | Ensure equipment is clean, maintained, and inspected with posted allowable tolerances | Preventive maintenance schedules, technician work order logs, periodic inspection records, tolerance placards | Overdue maintenance tasks, missing tolerance stickers on adjustable fixtures, uncalibrated tools | ISO 13485:2016 Clause 6.3 (Infrastructure maintenance) and Clause 7.5.1 |
| 820.70(h) Manufacturing Material Management | Control and remove manufacturing materials that could adversely affect device quality | Manufacturing material inventory, removal procedures, chemical residue test data, TOC wash logs | Unverified solvent or mold release residues, lack of residue toxicological evaluation | ISO 13485:2016 Clause 7.5.2 (Cleanliness of product - removal of manufacturing materials) |
| 820.70(i) Automated Processes & Software | Validate computer software used in production or quality systems for its intended use | Validation master plans, IQ/OQ/PQ protocols, challenge test results, change re-validation reports | Unvalidated spreadsheets for device release, untested PLC script updates, lack of protocol sign-off | ISO 13485:2016 Clause 4.1.6 (QMS software validation) and Clause 7.5.6 (Process software validation) |
Sources
- Legal Information Institute, Cornell Law School: 21 CFR § 820.70 - Production and process controls (accessed 2026-11-20)
- U.S. Government Publishing Office: 21 CFR 820.70 - Production and process controls (eCFR XML) (accessed 2026-11-20)
- Federal Register: Medical Devices; Quality System Regulation Amendments (QMSR Final Rule, 89 FR 7496) (accessed 2026-11-20)
- U.S. Food and Drug Administration: Quality Management System Regulation (QMSR) Overview (accessed 2026-11-20)
- U.S. Food and Drug Administration: General Principles of Software Validation (accessed 2026-11-20)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







